Mission Bio Launches Industry-First Single-cell Multi-omics Capabilities to Simultaneously Detect DNA and Protein from the Same Cell

 

As the first and only platform with these capabilities, the Tapestri Platform will enable key insights to drive the development of more impactful cancer therapies

 

SOUTH SAN FRANCISCO, Calif. (November 6, 2019) Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced its expansion into single-cell multi-omics. The company’s proprietary technology, the Tapestri Platform, is now the first-ever single-cell multi-omic platform capable of detecting DNA and protein changes simultaneously from the same cell — a capability necessary for the development of impactful precision therapies. The company has partnered with BioLegend, a global leader in protein antibody and reagent‎ manufacturing, to co-develop the first commercial solution for combined DNA and protein analysis at the single-cell level.

 

Only 3% of cancer drugs tested in clinical trials between 2000 and 2015 have been approved to treat patients, and even those that have been approved are not as effective as we’d hope. Even those aimed at specific biomarkers like DNA mutations aren’t effective in every patient with that mutation, resulting in high rates of relapse. Ultimately, the complexity of disease evolution and therapy response requires comprehensive tools to characterize how DNA mutations drive disease at the cellular level, including functional changes in protein. To develop durable therapies, we require a deeper understanding of all analytes of the cell.

 

“To better confront cancer and develop dynamic solutions that mirror the disease’s evolution, we require a more profound insight into every component that drives disease,” explained Nigel Beard, Senior Vice President, Research & Development at Mission Bio. “Our systems inherent technology allows us to probe multiple analytes at the same time from the same cell, enabling novel and integrated datasets. These new capabilities open up numerous applications, providing multi-omic insight into disease drivers so our customers can understand these complex biological mechanisms and accelerate cures.”

 

Through its extension into multi-omics, a market projected to reach $5 billion by 2025, Mission Bio’s Tapestri Platform is now the first and only single-cell multi-omic platform to simultaneously detect single nucleotide variants (SNVs), copy number variations (CNVs) and proteins from the same cell. With access to multiple layers of the cellular profile, the Tapestri Platform provides the insight necessary to develop the most precise treatments that target the right set of biomarkers in diseased cells, opening the door for more successful patient outcomes.

 

“Connecting the DNA mutational profile with the protein profile of the same cell is transforming our understanding of cancer, as this gives us the capability to connect somatic mutations to specific differentiation states, and to really understand how leukemia initiates and evolves. This is a game-changer when it comes to developing precise, effective treatments,” explained Ross Levine, MD, Chief of Molecular Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center, Human Oncology and Pathogenesis Program. “With this insight, we can see the past, present, and future of each person’s cancer, determine how it evolves, and develop new therapeutic approaches aimed to prevent disease evolution and relapse.”

 

Mission Bio’s Tapestri Single-Cell DNA Panels will enable SNV and CNV detection in combination with oligonucleotide-conjugated antibodies from BioLegend, providing dozens of protein targets that will be compatible with the Tapestri workflow.

 

“We are excited to work with Mission Bio to co-develop a novel multi-omics solution for researchers interested in pairing phenotypic and genotypic characterization from the same individual cell,” said Kristopher Nazor, Head of Proteogenomics at BioLegend. “This novel combination of data will play a critical role in enabling our customers to inform patient-specific therapeutic strategies.”

 

Mission Bio and BioLegend are currently co-developing a hematology-focused panel for commercial launch date in 2020. For those interested in learning more about SNV, CNV and protein capabilities on the Tapestri Platform, please contact Mission Bio directly at (missionbio.com/SNV-CNV-protein, info@missionbio.com).

 

Ross Levine’s Lab will present the findings of their work leveraging this technology on Wednesday, November 6th at AMP 2019 in Baltimore, Maryland. Mission Bio will also be part of the exhibition at booth 2749.

 

To learn more about Mission Bio and how it’s moving precision medicine forward, visit missionbio.com.

 

About Mission Bio
Mission Bio delivers targeted solutions for high impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell, and precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The company’s Tapestri Platform was also honored as a Top 10 Innovation of 2018 by The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. With Mission Bio, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.

 

Media Contact:

Kathryn Ryan

VSC for Mission Bio
missionbio@vscconsulting.com
(631) 255-5281